Melanotan II: The Tanning Peptide with a Complicated Story

LEGAL & MEDICAL DISCLAIMER: The information provided on this page by PeptideMatch.io is intended solely for educational and informational purposes. It does not constitute, and should not be interpreted as, professional medical advice, diagnosis, or treatment. Always consult a licensed physician or qualified healthcare provider before beginning any peptide therapy or making changes to an existing treatment plan. PeptideMatch.io does not prescribe, dispense, or endorse any specific therapeutic protocol. Individual results may vary, and no outcomes are guaranteed.

What Is Melanotan II?

In the early 1990s, researchers at the University of Arizona set out to solve what seemed like a simple problem: could you create a compound that tells the body to make its own melanin (the pigment that gives skin its color) without needing sun exposure?

The idea was appealing. If you could trigger the skin’s natural tanning response from the inside, you might protect fair-skinned people from the DNA damage caused by UV rays. The result of that research was melanotan II, a lab-made peptide designed to mimic alpha-MSH, the hormone your body naturally uses to signal melanin production.¹

But the story did not go as planned.

Melanotan II turned out to be a non-selective compound. That means it does not just flip the “tanning switch.” It activates several different receptor types throughout the body, triggering effects on sexual function, appetite, and blood pressure. This lack of precision made it unsuitable for drug development as a tanning product, though it did lead to the creation of two FDA-approved drugs that came from the same line of research: afamelanotide (for a rare light sensitivity disorder) and bremelanotide (for sexual dysfunction).²

Melanotan II itself, however, has never been approved by any regulatory body for any purpose. It’s only available through unregulated sources, and its use carries documented safety risks that anyone considering it should understand clearly.

Fast Facts

FULL NAME	Melanotan II (MT-II)
CLASS	Synthetic melanocortin receptor agonist; lab-made version of alpha-MSH
PRIMARY ACTION	Activates multiple receptor types (MC1R, MC3R, MC4R, MC5R), triggering melanin production while also affecting sexual function and appetite
ADMINISTRATION	In Phase I research, administered via subcutaneous injection under clinical supervision
HALF-LIFE	About 1 to 2 hours
RESEARCH	Skin pigmentation, photoprotection, sexual dysfunction (led to bremelanotide development)
REGULATORY STATUS	Not approved by the FDA or any other regulatory body worldwide for tanning or cosmetic use. Safety warnings issued by multiple agencies.

How Does Melanotan II Work?

Melanotan II works by copying a natural hormone your body already makes. But because it is non-selective (meaning it hits multiple targets at once), it triggers several systems in the body simultaneously. Understanding these pathways helps explain both the appeal and the risk.

1. Triggering Melanin Production (Skin Receptors) Melanotan II attaches to receptors on melanocytes, the cells in your skin that make pigment. This turns on an enzyme called tyrosinase, which ramps up production of eumelanin (the darker type of melanin). The result is a visible darkening of the skin, similar to a natural tan, but without needing sun exposure.¹
2. Activating Sexual Function Pathways (Brain Receptors) The same compound also attaches to receptors in the brain that are involved in sexual arousal. This was an accidental finding during early trials, when male subjects reported spontaneous erections. This pathway eventually led to the development of bremelanotide (brand name Vyleesi), an FDA-approved treatment for low sexual desire in women.²
3. Affecting Appetite and Metabolism Receptors in the brain that control hunger and energy balance are also activated by melanotan II. This has been linked to reduced food intake in both animal and human studies. However, this effect is not well enough understood to be considered a benefit, and it adds to the compound’s unpredictable side effect profile.²

The research on melanotan II is limited compared to many other peptides. Most of the clinical data comes from early-phase trials done in the 1990s, along with case reports and safety reviews published since then. PeptideMatch.io presents this data so our community can tell the difference between what has been studied in controlled settings and what is known from reports of unregulated use.

THERAPEUTIC AREA	WHAT RESEARCH SUGGESTS	EVIDENCE LEVEL
Skin Pigmentation	A Phase I trial confirmed melanotan II produces visible tanning in fair to medium skin after injection, without UV exposure.1	Phase 1
Sexual Function	Pro-erectile effects seen in early trials led to development of bremelanotide (PT-141), now FDA-approved for a different condition.2	Phase 1
Photoprotection	Research on the related compound afamelanotide (a more targeted version) showed protective benefit in a rare light sensitivity disorder, leading to FDA approval.2	Clinical (related compound)
Safety & Adverse Events	Case reports document kidney damage, muscle breakdown, and concerns about melanoma risk in users.3, 4	Case Reports
Mole Changes	Multiple reports of new moles appearing, existing moles getting darker, and unusual mole changes in users, raising skin cancer monitoring concerns.5	Case Reports

What the Phase I Trial Showed

The original 1996 study by Dorr and colleagues at the University of Arizona enrolled people with fair to medium skin. Participants received five low doses of melanotan II by injection every other day. The study confirmed that the compound could produce visible tanning without sun exposure. But it also documented a consistent pattern of side effects: facial flushing, nausea, tiredness, yawning, and in male subjects, spontaneous erections.¹

These side effects were a direct result of the compound hitting multiple receptor types at once. Because melanotan II cannot target just the tanning receptor without also affecting other systems, it was never advanced as a pharmaceutical product.

Melanotan II was never taken beyond Phase I trials for tanning. Its lack of precision led researchers to develop more targeted compounds: afamelanotide (now FDA-approved for a rare light disorder) and bremelanotide (now FDA-approved for low sexual desire).² The safety profile of melanotan II is the main reason it has never received regulatory approval. Unlike many peptides discussed in this series, melanotan II has a documented pattern of serious problems beyond the common side effects seen in trials.

Common Side Effects (Seen in Clinical Trials)

In the Phase I study and later reports, the following side effects were consistently seen: nausea (often bad enough to limit dosing), facial flushing, tiredness, headache, and yawning. In male subjects, spontaneous erections were reported often enough to be considered a drug effect rather than a one-off event.¹

Serious Problems (Published Case Reports)

Published case reports in medical journals have documented the following serious events in melanotan II users:

• Kidney damage: A case of kidney infarction (blocked blood flow to the kidney) linked to melanotan II use was published in BMC Nephrology in 2020.³
• Muscle breakdown: Rhabdomyolysis (a condition where muscle tissue breaks down and can damage the kidneys) was reported after melanotan II injection.⁴
• Skin cancer concern: Multiple case reports have documented new moles appearing, existing moles getting darker, and unusual changes in moles. Because melanotan II stimulates the cells that produce pigment, there is both a theoretical and observed concern that it may promote melanoma (skin cancer).⁵
• Heart and blood pressure effects: High blood pressure and stimulant-like symptoms have been reported.⁴

The Quality Problem

Because melanotan II is not made under pharmaceutical standards, products from unregulated sources have no quality control. Users cannot verify purity, strength, sterility, or whether contaminants are present. This adds another layer of risk on top of the compound’s own effects.

Important Considerations

Regulatory Status	Melanotan II is not approved by the FDA or any other regulatory body worldwide for any purpose. Multiple agencies have issued direct safety warnings against its use.
Not the Same as Approved Drugs	Melanotan II is often confused with its FDA-approved relatives. Afamelanotide (Scenesse) is approved only for a rare light sensitivity disorder. Bremelanotide (Vyleesi) is approved only for low sexual desire in women. Neither approval applies to melanotan II itself.
Skin Cancer Risk	Stimulating the cells that make pigment carries a theoretical and observed risk of promoting melanoma. Anyone with a history of skin cancer, unusual moles, or heavy sun damage should be especially aware of this concern.
No Quality Assurance	All melanotan II currently available comes from unregulated sources with no manufacturing oversight, no quality testing, and no guarantee of purity or sterility.

The Bottom Line: Melanotan II holds an unusual place in peptide science. The research that produced it was legitimate and led to two FDA-approved drugs. But the compound itself was never suitable for clinical development because it hits too many targets at once, causing side effects that cannot be separated from its tanning effect. For those studying melanocortin biology, melanotan II is an important historical compound. For those considering its use for cosmetic tanning, the evidence is clear: it carries documented risks including serious adverse events, potential skin cancer promotion, and the added danger of unregulated manufacturing. The fact that safer, approved alternatives exist for specific medical conditions shows exactly why melanotan II itself was never brought to market.

Scientific References

1. Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996;58(20):1777-1784.
2. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930.
3. Peters B, Hadimeri H, Grzechocinska J, Wieslander A, Christensen JH. Melanotan II: a possible cause of renal infarction. BMC Nephrology. 2020;21:113.
4. Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical Toxicology. 2012;50(10):1169-1173.
5. Evans-Brown M, Dawson RT, Chandler M, McVeigh J. Use of melanotan I and II in the general population. BMJ. 2009;338:b566.

©2026 PeptideMatch.io. All Rights Reserved. This educational content is the exclusive intellectual property of PeptideMatch.io. Reproduction, distribution, republication, or transmission of this material, in whole or in part, in any form or by any means, is strictly prohibited without the prior written consent of PeptideMatch.io. For licensing or reprint inquiries, please contact content@peptidematch.io.